[Skip to Content]
[Skip to Content Landing]
Views 954
Citations 0
Editorial
September 5, 2017

Human Immunodeficiency Virus Preexposure Prophylaxis for Adolescent MenHow Do We Ensure Health Equity for At-Risk Young Men?

Author Affiliations
  • 1Division of General Pediatrics & Adolescent Medicine, Johns Hopkins University, Baltimore, Maryland
JAMA Pediatr. Published online September 5, 2017. doi:10.1001/jamapediatrics.2017.2397

Preexposure prophylaxis (PrEP), coformulated as tenofovir (TFV), disoproxil fumarate (TDF), and emtricitabine (FTC), is a biomedical intervention that has demonstrated a reduction of human immunodeficiency virus (HIV) transmission rates by as much as 75% in heterosexual serodiscordant partnerships and up to 99% among men having sex with men (MSM) and transgender women when taken daily.1,2 It was approved by the US Food and Drug Administration in 2012 for adults 18 years and older, but approval for adolescents younger than 18 years has stalled because of limited data on the efficacy, acceptability, and safety among adolescents younger than 18 years.

First Page Preview View Large
First page PDF preview
First page PDF preview
×